Table 9.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1994 to 2003

Recipients with Liver Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 3,652 3,934 4,081 4,185 4,516 4,751 4,989 5,188 5,331 5,671
Tx with Antirejection Treatments 1,565 1,339 1,306 1,327 1,186 1,468 1,500 1,423 1,304 1,040
Antibodies Any in Category 30.4% 22.0% 13.2% 12.1% 13.1% 12.5% 14.5% 16.7% 17.5% 18.0%
ALG 1.4% 0.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 2.5% 1.4% 2.1% 1.4% 1.4% 0.7% 0.5% 0.5% 0.6% 0.8%
OKT3 28.0% 20.5% 11.9% 11.1% 9.7% 6.8% 6.3% 6.7% 6.0% 5.4%
Thymoglobulin 0.0% 0.0% 0.0% 0.0% 0.3% 1.4% 3.2% 5.1% 5.6% 7.0%
Zenapax 0.0% 0.0% 0.0% 0.2% 0.9% 1.7% 2.4% 1.6% 1.9% 1.4%
Simulect 0.1% 0.0% 0.0% 0.1% 1.2% 3.1% 3.1% 4.2% 4.0% 3.1%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.6% 2.0%
Corticosteroids Any in Category 86.1% 83.6% 83.7% 83.9% 87.4% 89.5% 90.7% 89.0% 90.3% 91.6%
Steroids 86.1% 83.6% 83.7% 83.9% 87.4% 89.5% 90.7% 89.0% 90.3% 91.6%
Antimetabolites Any in Category 0.4% 0.6% 0.2% 0.7% 0.3% 0.2% 0.1% 0.1% 0.0% 0.1%
Cytoxan 0.4% 0.6% 0.2% 0.7% 0.3% 0.2% 0.1% 0.1% 0.0% 0.1%
Methotrexate 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 2, 2005.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.